Shoulder Innovations, Inc. (NYSE:SI – Get Free Report) major shareholder Healthcare Holding B.V. Gilde sold 7,338 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $22.64, for a total value of $166,132.32. Following the transaction, the insider owned 2,214,302 shares in the company, valued at $50,131,797.28. This trade represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Healthcare Holding B.V. Gilde also recently made the following trade(s):
- On Thursday, August 6th, Healthcare Holding B.V. Gilde sold 2,095 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.60, for a total value of $47,347.00.
- On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.77, for a total transaction of $2,272,719.24.
- On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.71, for a total transaction of $244,155.21.
- On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.73, for a total transaction of $455,372.82.
- On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The shares were sold at an average price of $23.36, for a total transaction of $659,803.20.
Shoulder Innovations Stock Performance
Shoulder Innovations stock opened at $20.54 on Monday. The company has a quick ratio of 8.92, a current ratio of 10.71 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $427.71 million and a PE ratio of -10.70. The firm has a fifty day simple moving average of $19.91 and a two-hundred day simple moving average of $16.09. Shoulder Innovations, Inc. has a twelve month low of $10.92 and a twelve month high of $24.59.
Shoulder Innovations News Summary
Here are the key news stories impacting Shoulder Innovations this week:
- Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
- Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
- Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
- Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
- Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
- Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale
Institutional Investors Weigh In On Shoulder Innovations
A number of large investors have recently modified their holdings of the stock. Wells Fargo & Company MN increased its holdings in Shoulder Innovations by 66.3% in the 4th quarter. Wells Fargo & Company MN now owns 5,250 shares of the company’s stock worth $75,000 after buying an additional 2,094 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Shoulder Innovations during the 3rd quarter valued at about $28,000. Rhumbline Advisers bought a new position in Shoulder Innovations during the 3rd quarter valued at about $54,000. Bank of America Corp DE boosted its holdings in shares of Shoulder Innovations by 43.7% during the 1st quarter. Bank of America Corp DE now owns 26,983 shares of the company’s stock valued at $392,000 after acquiring an additional 8,205 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Shoulder Innovations in the fourth quarter worth approximately $176,000.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. BTIG Research upped their price objective on shares of Shoulder Innovations from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Friday. Piper Sandler restated an “overweight” rating and set a $25.00 price target (up from $19.00) on shares of Shoulder Innovations in a report on Friday. Weiss Ratings raised Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Finally, UBS Group initiated coverage on Shoulder Innovations in a research report on Tuesday, July 28th. They issued a “buy” rating and a $27.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.
Shoulder Innovations Company Profile
Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.
In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.
Read More
- Five stocks we like better than Shoulder Innovations
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Shoulder Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shoulder Innovations and related companies with MarketBeat.com's FREE daily email newsletter.
